Regeneron Pharmaceuticals vs United Therapeutics
Regeneron Pharmaceuticals (REGN) and United Therapeutics (UTHR) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $95.2B
- Last close
- $920.69
- 12 months
- +24.9%
- Market value
- $23.6B
- Last close
- $554.73
- 12 months
- +16.9%
At a glance
- The biggest part of Regeneron Pharmaceuticals's revenue is Collaboration revenue (51%); at United Therapeutics it is Tyvaso DPI (41%).
- By market value, Regeneron Pharmaceuticals ($95.2B) is about 4.0 times United Therapeutics ($23.6B).
- Over the last 12 months Regeneron Pharmaceuticals's share price moved +24.9% and United Therapeutics's +16.9%; against the S&P 500 that is +19.2 points and +11.1 points.
- In their last fiscal years Regeneron Pharmaceuticals kept 31.4% of revenue as net income and United Therapeutics 41.9%.
- In the last 90 days insiders reported 0 open-market purchases at Regeneron Pharmaceuticals and 0 at United Therapeutics; members of Congress disclosed 0 trades in Regeneron Pharmaceuticals and 0 in United Therapeutics.
- Next results: Regeneron Pharmaceuticals Jan 28, 2027, United Therapeutics Feb 23, 2027.
How each one makes money: Regeneron Pharmaceuticals revenue · United Therapeutics revenue
Share prices on one chart
Regeneron Pharmaceuticals and United Therapeutics, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Regeneron Pharmaceuticals REGNNASDAQ · Biotechnology | United Therapeutics UTHRNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $95.2B | $23.6B |
| Revenue, last fiscal year | $14.3B | $3.18B |
| Net income, last fiscal year | $4.5B | $1.33B |
| Net marginNet income as a share of revenue | 31.4% | 41.9% |
| Free cash flow | $4.08B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Regeneron Pharmaceuticals against
Common questions
How is Regeneron Pharmaceuticals different from United Therapeutics?
Regeneron Pharmaceuticals (REGN) is in Biotechnology on NASDAQ, with $14.3B of revenue in its last fiscal year and a net margin of 31.4%. United Therapeutics (UTHR) is in Biotechnology on NASDAQ, with $3.18B of revenue in its last fiscal year and a net margin of 41.9%. The biggest part of Regeneron Pharmaceuticals's revenue is Collaboration revenue (51%); at United Therapeutics it is Tyvaso DPI (41%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Regeneron Pharmaceuticals and United Therapeutics compare in size?
Regeneron Pharmaceuticals has the larger market value: Regeneron Pharmaceuticals $95.2B and United Therapeutics $23.6B, at the last close.
Whose share price rose more over the last 12 months, REGN or UTHR?
Over the last 12 months Regeneron Pharmaceuticals moved +24.9% and United Therapeutics +16.9%. Past price moves say nothing about the future.
Which has had more insider buying, Regeneron Pharmaceuticals or United Therapeutics?
Since 2006, Regeneron Pharmaceuticals insiders reported 551 open-market purchases against 43 for United Therapeutics. These are counts of what was filed, not a view on either stock.
Do members of Congress trade REGN or UTHR?
In the last 12 months, members of Congress disclosed 4 trades in Regeneron Pharmaceuticals (REGN) and 0 in United Therapeutics (UTHR).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Regeneron Pharmaceuticals pageUnited Therapeutics pageRare insider trades this weekAll comparisons
https://oqro.io/compare/regn-vs-uthr







